Skip to main content

Table 1 Baseline clinical characteristics of study subjects

From: Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Variables Total enrolled patients (n = 41) UI-EWD monotherapy (n = 23)
Age (year)§ 74 (39–88) 76 (39–88)
Gender (Male), n (%) 31 (75.6) 32 (74.4)
The tumor pathology, n (%)   
Adenocarcinoma 33 (80.5) 17 (73.9)
Squamous carcinoma 2 (4.9) 0 (0.0)
GIST 5 (12.2) 4 (17.4)
Lymphoma 1 (2.4) 2 (8.7)
Tumor stage, n (%)   
1 3 (7.3) 2 (7.0)
2 2 (4.9) 0 (9.3)
3 6 (14.6) 3 (16.3)
4 30 (73.2) 18 (67.4)
ASA score, (%)   
1 2 (4.9) 1 (4.3)
2 7 (17.1) 4 (17.4)
3 18 (43.9) 10 (43.5)
4 13 (31.7) 7 (30.4)
5 1 (2.4) 1 (4.3)
Comorbidity, n (%)   
HTN 18 (43.9) 12 (47.8)
DM 12 (29.3) 5 (21.7)
Cardiovascular 13 (31.7) 7 (30.4)
CKD 4 (9.8) 2 (8.7)
Systolic blood pressure (mmHg)§ 108 (74–162) 108 (74–139)
Diastolic blood pressure (mmHg)§ 59 (30–96) 59 (30–91)
Heart rate (per min)§ 92 (51–177) 84 (51–177)
Hb (g/dL)§ 6.7 (3.7–14.0) 6.7 (3.7–14.0)
Follow up duration (day) § 107 (7–956) 57 (7–607)
  1. ASA, American society of anesthesiologist; CKD, chronic kidney disease; DM, diabetes mellitus; GIST, gastrointestinal stromal tumor; Hb, hemoglobin; HTN, hypertension
  2. §, median (range)